Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-17-3668. [Epub ahead of print]

PMID:
30082477
2.

Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.

Dai B, Roife D, Kang Y, Gumin J, Rios Perez MV, Li X, Pratt M, Brekken RA, Fueyo-Margareto J, Lang FF, Fleming JB.

Mol Cancer Ther. 2017 Apr;16(4):662-670. doi: 10.1158/1535-7163.MCT-16-0526. Epub 2017 Jan 30.

3.

Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors.

Kang Y, Roife D, Lee Y, Lv H, Suzuki R, Ling J, Rios Perez MV, Li X, Dai B, Pratt M, Truty MJ, Chatterjee D, Wang H, Thomas RM, Wang Y, Koay EJ, Chiao PJ, Katz MH, Fleming JB.

Clin Cancer Res. 2016 Oct 1;22(19):4934-4946. Epub 2016 Apr 28.

4.

Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay.

Rios Perez MV, Dai B, Koay EJ, Wolff RA, Fleming JB.

Cureus. 2015 Dec 21;7(12):e423. doi: 10.7759/cureus.423.

Supplemental Content

Loading ...
Support Center